From the Headache Diagnostic Laboratory (T.P.D., H.W.S.), Danish Headache Center and Department of Neurology (J.M.H.), Rigshospitalet-Glostrup, Faculty of Health Sciences, University of Copenhagen, Glostrup, Denmark; Department of Neurology (A.R., G.G.S.), Elisabeth-TweeSteden Hospital, Tilburg, the Netherlands; Department of Neurology (C.S.), Inselspital, Bern University Hospital, University of Bern, Switzerland; Department of Neurology and Anesthesiology/Critical Care Medicine (S.E.N.), Johns Hopkins University, Baltimore, MD; Center for Neurology (M.O.), Asklepios Hospitals Schildautal, Seesen; Department of Neurology (M.O.), University Hospital Essen, University of Duisburg-Essen, Germany; Neurometabolism (A.J.S.), Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, UK; and Neurorehabilitation (A.R.G.), RehaClinic Bad Zurzach and University of Zürich, Switzerland.
Neurology. 2019 Jan 15;92(3):134-144. doi: 10.1212/WNL.0000000000006697. Epub 2018 Dec 26.
A minority of headache patients have a secondary headache disorder. The medical literature presents and promotes red flags to increase the likelihood of identifying a secondary etiology. In this review, we aim to discuss the incidence and prevalence of secondary headaches as well as the data on sensitivity, specificity, and predictive value of red flags for secondary headaches. We review the following red flags: (1) systemic symptoms including fever; (2) neoplasm history; (3) neurologic deficit (including decreased consciousness); (4) sudden or abrupt onset; (5) older age (onset after 65 years); (6) pattern change or recent onset of new headache; (7) positional headache; (8) precipitated by sneezing, coughing, or exercise; (9) papilledema; (10) progressive headache and atypical presentations; (11) pregnancy or puerperium; (12) painful eye with autonomic features; (13) posttraumatic onset of headache; (14) pathology of the immune system such as HIV; (15) painkiller overuse or new drug at onset of headache. Using the systematic SNNOOP10 list to screen new headache patients will presumably increase the likelihood of detecting a secondary cause. The lack of prospective epidemiologic studies on red flags and the low incidence of many secondary headaches leave many questions unanswered and call for large prospective studies. A validated screening tool could reduce unneeded neuroimaging and costs.
少数头痛患者存在继发性头痛障碍。医学文献提出并推广了一些警示症状,以增加识别继发性病因的可能性。在本次综述中,我们旨在讨论继发性头痛的发病率和患病率,以及警示症状对继发性头痛的敏感性、特异性和预测值的数据。我们回顾了以下警示症状:(1)全身症状,包括发热;(2)肿瘤病史;(3)神经功能缺损(包括意识下降);(4)突发或急剧发作;(5)年龄较大(65 岁以后发病);(6)模式改变或新发头痛近期发作;(7)位置性头痛;(8)打喷嚏、咳嗽或运动诱发;(9)视乳头水肿;(10)进行性头痛和不典型表现;(11)妊娠或产褥期;(12)伴有自主神经症状的疼痛性眼部疾病;(13)创伤后头痛发作;(14)免疫系统疾病,如 HIV;(15)止痛药滥用或头痛发作时使用新药物。使用系统的 SNNOOP10 清单对新发头痛患者进行筛查,可能会增加检测到继发性病因的可能性。缺乏对警示症状的前瞻性流行病学研究,以及许多继发性头痛的发病率较低,使得许多问题仍未得到解答,需要进行大型前瞻性研究。一个经过验证的筛查工具可以减少不必要的神经影像学检查和费用。